within Pharmacolibrary.Drugs.ATC.S;

model S01XA21
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 4.9999999999999996e-06,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01XA21</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Mercaptamine, also known as cysteamine, is a thiol compound used primarily to treat cystinosis, a rare genetic lysosomal storage disorder. Ophthalmic formulations are used to treat corneal crystal accumulation in cystinosis patients. The drug works by reducing intralysosomal cystine levels. Mercaptamine ophthalmic solution is currently approved for use.</p><h4>Pharmacokinetics</h4><p>No direct pharmacokinetic parameters for mercaptamine (cysteamine) ophthalmic solution (S01XA21) are available in published literature for the ophthalmic route. The following parameters are estimated based on general small-molecule ophthalmic PK models and nonclinical references.</p><h4>References</h4><ol><li><p>Jimenez, J, et al., &amp; DiLeo, MV (2022). Ocular biodistribution of cysteamine delivered by a sustained release microsphere/thermoresponsive gel eyedrop. <i>International journal of pharmaceutics</i> 624 121992–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2022.121992&quot;>10.1016/j.ijpharm.2022.121992</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35809831/&quot;>https://pubmed.ncbi.nlm.nih.gov/35809831</a></p></li><li><p>Ijaz, M, et al., &amp; Bernkop-Schnürch, A (2016). Thiolated α-Cyclodextrin: The Invisible Choice to Prolong Ocular Drug Residence Time. <i>Journal of pharmaceutical sciences</i> 105(9) 2848–2854. DOI:<a href=&quot;https://doi.org/10.1016/j.xphs.2016.04.021&quot;>10.1016/j.xphs.2016.04.021</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27233687/&quot;>https://pubmed.ncbi.nlm.nih.gov/27233687</a></p></li><li><p>Hsuan, JD, et al., &amp; Bron, AJ (1996). The penetration of topical cysteamine into the human eye. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 12(4) 499–502. DOI:<a href=&quot;https://doi.org/10.1089/jop.1996.12.499&quot;>10.1089/jop.1996.12.499</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8951686/&quot;>https://pubmed.ncbi.nlm.nih.gov/8951686</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01XA21;
